A new approach to treating breakthrough bleeds for FVIII inhibitor patients when using concomitant aPCC

Talk to patients and caregivers about how HEMLIBRA® increases coagulation potential




aPCC=activated prothrombin complex concentrate; BPAs=bypassing agents; FVIII=factor VIII; TMA=thrombotic microangiopathy.
*Monitoring includes D-dimer, prothrombin fragment F1+2 (if available), platelet count, serum creatinine, LDH, and peripheral blood smear analysis for schistocytes. For patients who require multiple BPA doses, laboratory monitoring should be performed every 24-48 hours thereafter until 24-48 hours following the last BPA dose administered to treat a given bleed. 4

Treating Breakthrough Bleeds

Guidelines for addressing breakthrough bleeds

Dosing Calculator 

Help calculate the dosage for your HEMLIBRA patient

Laboratory Monitoring Information

Considerations for using laboratory tests to monitor patients taking HEMLIBRA